ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > So,it's the first day of the JP Morgan Healthcare Conference

<< Previous

Bullboard Posts

Next >>

Comment by BottomBrokeron Jan 09, 2023 4:18pm

151 Views

Post# 35211996

RE:RE:RE:RE:So,it's the first day of the JP Morgan Healthcare Conference

I don't know if I share your level of cyncisim when it comes to the FDA, but I get what you're saying.

But going back to bball's post, saying that no one knows when the IND will be filed....why then did Promis say it would be filed in December? Why make promises they can't keep? As goldtech previously pointed out, broken promises, NO NEWS kills the share price. And then we've got that much further to climb back to where we started.

Anyway, that's enough venting for today.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments